# Immunotherapy

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/immunotherapy/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 1750-743X |
| ISSNs | 1750-743X,1750-7448 |
| OpenAlex ID | https://openalex.org/S71887004 |
| Publisher | Future Medicine |

## Journal papers

- [Immune Recognition and Rejection of Allogeneic Skin Grafts](https://scholariq.org/papers/immune-recognition-and-rejection-of-allogeneic-skin-grafts/)
- [Activation of Aryl Hydrocarbon Receptor by Tcdd Prevents Diabetes in Nod Mice and Increases Foxp3 <sup>+</sup> T Cells in Pancreatic Lymph Nodes](https://scholariq.org/papers/activation-of-aryl-hydrocarbon-receptor-by-tcdd-prevents-diabetes-in-nod-mice/)
- [Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies](https://scholariq.org/papers/immunotherapy-for-alzheimer-s-disease-from-anti-amyloid-to-tau-based/)
- [Separating Graft-Versus-Leukemia From Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation](https://scholariq.org/papers/separating-graft-versus-leukemia-from-graft-versus-host-disease-in-allogeneic/)
- [Progressive Diffuse Large B-cell Lymphoma with <i>TP53</i> Gene Mutation Treated with Chidamide-Based Chemotherapy](https://scholariq.org/papers/progressive-diffuse-large-b-cell-lymphoma-with-i-tp53-i-gene-mutation-treated/)
- [Upadacitinib for Moderate to Severe Atopic Dermatitis](https://scholariq.org/papers/upadacitinib-for-moderate-to-severe-atopic-dermatitis/)
- [Chemotherapy or Chemo-Immunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer: A Meta-Analysis](https://scholariq.org/papers/chemotherapy-or-chemo-immunotherapy-as-first-line-treatment-for-extensive-stage/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.